Pamela Lapham

Pamela (Davol) Lapham is an accomplished regulatory affairs professional with extensive experience in the biopharmaceutical and medical device industries. Currently serving as Vice President of Regulatory Affairs at Thymmune Therapeutics, Pamela leads regulatory strategies for iPSC product development targeting thymic-related disorders. Previous roles include Senior Director of Regulatory Affairs at Oxular and Genocea, where Pamela managed regulatory submissions and strategies for medical products, including ophthalmic drugs and immunotherapies. Their diverse background includes leadership in clinical and regulatory affairs at ProMedDx and project management at Ximedica, among others. With a Bachelor of Science in Biology from the University of Massachusetts Dartmouth and an Advanced Certification in Regulatory Affairs from San Diego State University, Pamela has demonstrated expertise in navigating complex regulatory landscapes and achieving timely submissions for clinical trials and marketing approvals.